Drug intelligence / Profile preview

INDV-1000

Development stage: Unknown
Lead developer: Indivior
Modality: Small Molecules

Overview

INDV-1000 is a selective positive allosteric modulator (PAM) of the GABA-B receptor being developed as a therapy for substance-related disorders, including alcohol use disorder and cannabis use disorder. It aims to enhance the effect of endogenous GABA at the GABA-B receptor, potentially reducing craving and relapse, and is under development by Indivior and Addex Therapeutics. Preclinical and early-phase trials focus on its use in the treatment of addiction and withdrawal therapies.

Other names: INDV 1000INDV1000INDV-1000GABA BPam

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on INDV-1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INDV-1000.

Explore the full profile